Jane Street’s Genmab GMAB Stock Holding History

Jane Street’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.82M	Buy	105,100 +65,700	+167%	+$1.97M	﹤0.01%	4461
2025 Q4	$1.21M	Buy	39,400 +22,900	+139%	+$714K	﹤0.01%	5755
2025 Q3	$506K	Buy	+16,500	New	+$402K	﹤0.01%	7835
2022 Q4	–	Sell	-42,900	Closed	-$1.38M	–	9479
2022 Q3	$1.38M	Buy	+42,900	New	+$1.51M	﹤0.01%	4848
2021 Q4	–	Sell	-90,300	Closed	-$3.95M	–	10341
2021 Q3	$3.95M	Buy	+90,300	New	+$4.05M	﹤0.01%	3135
2020 Q4	–	Sell	-11,500	Closed	-$416K	–	7706
2020 Q3	$416K	Buy	+11,500	New	+$416K	﹤0.01%	5438

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Jane Street's GMAB Position: Q1 2026 in Review

Jane Street opened a new position in Genmab (GMAB) in Q1 2026: 98,432 shares worth $2.64M. The stake represents ﹤0.01% of the portfolio and ranks #4576 among its holdings. This is a return to the name: Jane Street previously reported a position in GMAB as recently as Q2 2025.

Jane Street first reported a position in GMAB in Q3 2019 and has held it in 15 quarters since. The position peaked at $7.73M in Q1 2023. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Jane Street held 98,432 shares of Genmab worth $2.64M as of Q1 2026.
Genmab was a new Jane Street position in Q1 2026.
Genmab made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4576 holding.
Jane Street first reported a position in Genmab in Q3 2019 and has held it in 15 quarters since.
Jane Street's Genmab position peaked at $7.73M in Q1 2023.
272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.